Biotech Candidates
Biotech Candidates
Biotech Candidates — June 16, 2026
Overview
Biotech coverage contracted this cycle: ABBV, AMGN, GILD, ISRG, and REGN are no longer present in the current biotech.json summary and are omitted from this report. The remaining universe shows sharp divergence. MRNA is the biggest positive shift: $55.40, RSI 64.4, +15.15% 30D, strong-up — a dramatic recovery from RSI 44.2 drifting in May. LLY continues extending: $1,122.50, RSI 60.3, +13.6% 30D, strong-up, now -5.09% from ATH. NTLA steady at $14.55, RSI 56.6, +14.66% 30D, strong-up golden cross. VRTX holding: $453.17, RSI 58.6, +3.8% 30D, up trend. Negative flips: CRSP reversed from RSI 60.2 surprise recovery to strong-down at RSI 50.1, -33.72% from ATH. TMO deteriorated from RSI 62.3 recovering to strong-down at RSI 50.1, -26.61% from ATH. New entry: IBRX at $6.72, RSI 39, -16% 30D, -45.94% from ATH — oversold but in a weak-down trend.
| Signal | Reading |
|---|---|
| Overall | 🟡 Biotech mixed — LLY/MRNA leading; CRSP/TMO flipped strong-down; IBRX new oversold entry |
| Key insight | MRNA's RSI 44→64 recovery with +15.15% 30D is the most significant shift this cycle — the mRNA platform thesis may be repricing. CRSP and TMO both flipping to strong-down from prior recovery signals confirms gene-editing/CRO demand remain structurally challenged. |
Candidates
| Ticker | Price | RSI | Trend | 7D | 30D | 52wkHi | Signal | Take |
|---|---|---|---|---|---|---|---|---|
| LLY | $1,122.50 | 60.3 | strong-up | -2.63% | +13.6% | -5.1% | GC | GLP-1 thesis extending. +2.1% vs SMA20. Near ATH. -2.63% 7D pullback into GC — hold with trailing stops. |
| MRNA | $55.40 | 64.4 | strong-up | +10.58% | +15.15% | -7.0% | GC | MAJOR RECOVERY. RSI 44→64, +10.58% 7D. +14.8% vs SMA20. Strong-up GC confirmed. mRNA thesis repricing. |
| NTLA | $14.55 | 56.6 | strong-up | +11.0% | +14.66% | -48.5% | GC | Steady recovery. +10.4% vs SMA20. Golden cross intact. Still -48.5% from ATH — high risk/reward zone. |
| VRTX | $453.17 | 58.6 | up | +1.56% | +3.8% | -10.8% | GC | Holding strong. +3.0% vs SMA20. Golden cross. CF franchise steady. Quiet accumulation zone. |
| IBRX | $6.72 | 39 | weak-down | -0.56% | -16.0% | -45.9% | DC | NEW ENTRY. Oversold RSI 39. -16% 30D, -45.94% from ATH. -8.7% vs SMA20. Weak-down DC — no floor signal yet. Watch only. |
| CRSP | $52.02 | 50.1 | strong-down | +1.51% | +7.13% | -33.7% | DC | REVERSAL. Flipped to strong-down from prior RSI 60.2 recovery bounce. -33.72% from ATH. Death cross. The May bounce was a head-fake. |
| TMO | $472.63 | 50.1 | strong-down | -3.47% | +7.04% | -26.6% | DC | Flipped strong-down from prior recovery signal. -26.61% from ATH. +0.4% vs SMA20. Death cross. CRO demand thesis challenged. |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | LLY | GLP-1 runway intact. Strong-up GC, RSI 60, near ATH. -2.63% 7D is normal consolidation — hold with SMA20 trailing stops |
| 📈 ACCUMULATE | MRNA | RSI 44→64 recovery, +15.15% 30D, strong-up GC confirmed. Best biotech momentum shift this cycle. Initiate or add |
| 🔒 HOLD | VRTX | Strong GC, RSI 58, +3.8% 30D. CF franchise resilient. Hold — not the flashy entry but durable |
| 🔍 WATCH | NTLA | Strong-up GC, +14.66% 30D. -48.5% from ATH provides upside room but small-cap risk. Watch RSI hold above 50 |
| 🔍 WATCH | IBRX | RSI 39 approaching oversold territory. Weak-down DC means no buy yet — watch for RSI 30 floor + trend stabilization signal |
| ❌ DON'T BUY | CRSP | Strong-down DC confirmed. -33.7% from ATH. The May RSI 60 bounce has fully reversed. No floor signal. |
| ❌ DON'T BUY | TMO | Strong-down DC, -26.61% from ATH. The prior "recovery signal" at RSI 62 failed. Wait for RSI 35-40 floor. |
What Changed vs 05/29
Coverage narrowed: ABBV, AMGN, GILD, ISRG, and REGN (the RSI 27.3 extreme oversold strong buy from May) dropped out of the current biotech.json snapshot — their current status is unknown. Most significant positive change: MRNA recovered dramatically from RSI 44.2 drifting to RSI 64.4, +15.15% 30D, strong-up GC — the biggest shift in the group. NTLA steady at RSI 56.6 (+11% 7D this week). LLY extended to $1,122.50. Two critical negative reversals: CRSP flipped from RSI 60.2 surprise bounce to strong-down DC; TMO flipped from RSI 62.3 recovery to strong-down DC. New entry IBRX joins in weak-down oversold territory (-16% 30D, RSI 39).
Key Discoveries
| Discovery | Implication |
|---|---|
| MRNA RSI 44→64, +15.15% 30D, strong-up | mRNA platform thesis repricing — not just a bounce. Worth watching for sustained institutional accumulation above SMA20 |
| CRSP RSI 60→50.1, flipped to strong-down DC | The May gene-editing recovery was a head-fake — sector-wide CRO/gene-editing structural headwinds remain unresolved |
| TMO strong-down DC at RSI 50 after prior RSI 62 bounce | Lab equipment/CRO demand bottoming signal from May 29 was false — TMO -26.6% from ATH with DC confirms CRO demand thesis still challenged |
Open Questions
- MRNA at RSI 64.4 strong-up: is this a fundamental mRNA pipeline catalyst or beta bounce from broader market? Watch RSI 60 hold as momentum confirmation.
- REGN, ABBV, AMGN, GILD, ISRG dropped from biotech.json: watchlist coverage change or data gap? Confirm current status before any position changes on those names.
- IBRX at RSI 39 weak-down: is this approaching a capitulation floor (like REGN was at RSI 27.3 in May) or continued deterioration? No buy signal yet — watch -45.94% ATH for context on scale of drawdown.
Related
10 eventsNo direct external sources are attached to this read.